Authors: TOMLINSON PW CRAIG JC MOFFATT AR ROBERTS NA SHELDON JG WHITTAKER L DUNCAN IB

Citation: Pw. Tomlinson et al., HIV-1 FROM PATIENTS IN A PHASE-II CLINICAL-TRIAL WITH THE PROTEINASE-INHIBITOR (PI) SAQUINAVIR (SQV) TAKEN IN COMBINATION WITH RT INHIBITORS (RTIS) EXHIBITS VERY LITTLE REDUCED SENSITIVITY TO OTHER PIS, AIDS, 10, 1996, pp. 12-12

Authors: CRAIG C RACE E SHELDON J WHITTAKER L TOMLINSON PW MOFFAT A GILBERT S DUNCAN IB ROBERTS NA

Citation: C. Craig et al., SAQUINAVIR (SQV) DOES NOT SELECT FOR UNIVERSAL CORESISTANCE WITH OTHER PROTEINASE-INHIBITORS (PI) IN PATIENTS, AIDS, 10, 1996, pp. 13-13

Authors: RACE E GILBERT SM SHELDON JG MOFFAT AR TOMLINSON PW DUNCAN IB

Citation: E. Race et al., LOW OCCURRENCE OF REDUCED SENSITIVITY TO SAQUINAVIR IN ANTIVIRAL COMBINATION - RESULTS FROM A PHASE-III CLINICAL-TRIAL (NV-14256), AIDS, 10, 1996, pp. 15-15

Authors: WHITTAKER L SCHAPIRO JM CRAIG JC WINTERS MA TOMLINSON PW SHELDON JG MOFFATT AR JACOBSEN H DUNCAN IB GILBERT S CRAWFORD S MERIGAN TC

Citation: L. Whittaker et al., AN ASSESSMENT OF PHENOTYPIC AND GENOTYPIC CORESISTANCE TO INHIBITORS OF HIV PROTEINASE FOLLOWING THERAPY WITH HIGH-DOSE SAQUINAVIR, AIDS, 10, 1996, pp. 17-17

Authors: RACE E GILBERT SM SHELDON JG MOFFAT AR TOMLINSON PW DUNCAN IB

Citation: E. Race et al., AN OVERVIEW OF DRUG-RESISTANCE DURING SAQUINAVIR TREATMENT, AIDS, 10, 1996, pp. 25-25